Navigation Links
Osteoporosis drugs compared for side effects, efficacy in Loyola study
Date:12/2/2013

A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. These findings were presented recently at the American Society for Bone and Mineral Research's annual meeting.

Researchers performed a retrospective chart review and survey of 107 patients to compare the efficacy, patient satisfaction, cost and known adverse effects of denosumab versus zoledronic acid, including muscle pain, back pain and flulike symptoms. The denosumab and zoledronic acid groups were statistically similar in all areas but spine bone mineral density (increased 0.060 g/cm2 versus 0.021 g/cm2, respectively) and flulike symptoms (none versus 29 percent of patients).

"Both groups of patients were satisfied with their treatment despite the discrepancies in the drugs," said Kellen Sheedy, first author and Stritch School of Medicine student.

The FDA approved denosumab in 2010 for postmenopausal women with osteoporosis. It is injected subcutaneously (60 mg) every six months. The treatment works by inhibiting bone loss and fracture risk.

Zoledronic acid was approved by the FDA in 2007 for osteoporosis. This treatment is administered intravenously (5 mg) once every 12 months. It is the most potent of the drugs in its class, and it works by interfering with the bone-breakdown process.

"This study helped us quantify the efficacy and adverse effects of these two drugs providing further guidance for physicians who prescribe these treatments," said Pauline Camacho, MD, study investigator and director of the Osteoporosis & Metabolic Bone Disease Center at Loyola University Health System. "While this was the first head-to-head comparison of these two treatments, larger prospective studies will be needed to confirm these findings."


'/>"/>

Contact: Nora Dudley
nodudley@lumc.edu
708-216-6268
Loyola University Health System
Source:Eurekalert

Page: 1

Related medicine news :

1. Certain Genetic Regions May Be Tied to Osteoporosis
2. Experts recommend men at risk for osteoporosis undergo bone density testing
3. US Drug Watchdog Now Offers To Help Women Who Used TheOsteoporosis Drug Called Fosamax And Then Had A Unexplainable Femur Fracture Get To The Best Attorneys Or Law Firms
4. US Drug Watchdog Now Offers to Help All Woman Who Used Fosamax For Osteoporosis and Then Had an Unexplained a Femur Break Get to the Best Attorneys
5. ASBMR task force urges use of fracture liaision services to reduce costly osteoporosis bone breaks
6. Meeting in Jordan to educate medical professionals on latest advances in osteoporosis
7. Major IOF osteoporosis meeting to take place in Kuala Lumpur, Malaysia
8. Teen Girls Need Bone Health Advice to Stave Off Osteoporosis
9. Has osteoporosis treatment failed when a fracture occurs?
10. Men May Benefit From Osteoporosis Drug, Too: Study
11. Men with belly fat at risk for osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a leading provider ... magazine has named the company a “Top 25 Cybersecurity Companies 2017.” Axiad ... help organizations simply and proactively address potential cybersecurity threats before they happen. The ...
(Date:5/23/2017)... ... 23, 2017 , ... PM360, the premier information resource for ... winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders • ... industry today. , Out of more than 500 submissions, 100 winners were selected ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of ... Worthy of a Policy Response”, -The Rory Staunton Foundation Calls on Health & Human ... the Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study released ...
(Date:5/23/2017)... ... 23, 2017 , ... The National Council on Strength and ... the organization’s Certified Strength Coach credential has earned accreditation from the National Commission ... the competency of qualified candidates for jobs in the Strength and Conditioning profession. ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment option called ... elastin in their face, neck, and body through a virtually pain-free, non-surgical treatment. ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
Breaking Medicine Technology: